

# Merus

## Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023

May 31, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- [Merus N.V.](#) (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclronics<sup>®</sup> and Triclronics<sup>®</sup>), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference 2023 on Wednesday, June 7, 2023 at 11:30 a.m. ET.

The webcast of the presentation will be contemporaneously available on the [investors page](#) of the Company's website. The archived presentation will also be available there for a limited time after the event.

### About Merus

[Merus](#) is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as [Multiclronics<sup>®</sup>](#). Multiclronics<sup>®</sup> are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit [Merus' website](#), and [Twitter](#).

Multiclronics<sup>®</sup>, Biclronics<sup>®</sup> and Triclronics<sup>®</sup> are registered trademarks of Merus N.V.

### Investor and Media Inquiries:

Sherri Spear  
Merus N.V.  
VP Investor Relations and Corporate Communications  
617-821-3246  
[s.spear@merus.nl](mailto:s.spear@merus.nl)

Kathleen Farren  
Merus N.V.  
IR/Corp Comms  
617-230-4165  
[k.farren@merus.nl](mailto:k.farren@merus.nl)

# Merus